The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination.
Monk
Bradley J
BJ
Herzog
Thomas J
TJ
D003362:Cost-Benefit Analysis; D005260:Female; D017408:Guidelines as Topic; D006801:Humans; D008403:Mass Screening / Q000191:economics / Q000379:methods; D027383:Papillomaviridae / Q000254:growth & development*; D030361:Papillomavirus Infections / Q000150:complications / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000191:economics; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000191:economics / Q000517:prevention & control* / Q000821:virology; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis / Q000191:economics / Q000517:prevention & control* / Q000821:virology
D053918:Papillomavirus Vaccines